Indaptus Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Indaptus Therapeutics Current Ratio Growth & History (INDP)
Indaptus Therapeutics's current ratio was 1.51 for fiscal 2025.
View full Indaptus Therapeutics company overviewIndaptus Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.51 | −0.44 | −22.48% |
| 2024 | 2024-12-31 | 1.95 | −3.10 | −61.35% |
| 2023 | 2023-12-31 | 5.05 | −2.89 | −36.42% |
| 2022 | 2022-12-31 | 7.94 | −0.84 | −9.54% |
| 2021 | 2021-12-31 | 8.77 | 7.91 | +920.77% |
| 2020 | 2020-12-31 | 0.86 | — | — |
Indaptus Therapeutics quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 19.48 | 18.73 | +2485.62% |
| Q1 2026 | 2026-03-31 | 2.34 | 0.44 | +23.07% |
| Q4 2025 | 2025-12-31 | 1.51 | −0.44 | −22.48% |
| Q3 2025 | 2025-09-30 | 2.88 | −0.54 | −15.67% |
| Q2 2025 | 2025-06-30 | 0.75 | −3.13 | −80.60% |
| Q1 2025 | 2025-03-31 | 1.90 | −4.80 | −71.63% |
| Q4 2024 | 2024-12-31 | 1.95 | −3.10 | −61.35% |
| Q3 2024 | 2024-09-30 | 3.42 | −3.70 | −52.01% |
| Q2 2024 | 2024-06-30 | 3.88 | −5.57 | −58.90% |
| Q1 2024 | 2024-03-31 | 6.70 | −5.46 | −44.92% |
| Q4 2023 | 2023-12-31 | 5.05 | −2.89 | −36.42% |
| Q3 2023 | 2023-09-30 | 7.12 | −3.15 | −30.67% |
| Q2 2023 | 2023-06-30 | 9.45 | 0.27 | +2.92% |
| Q1 2023 | 2023-03-31 | 12.15 | 2.12 | +21.14% |
| Q4 2022 | 2022-12-31 | 7.94 | −0.84 | −9.54% |
| Q3 2022 | 2022-09-30 | 10.27 | 2.69 | +35.40% |
| Q2 2022 | 2022-06-30 | 9.18 | 5.73 | +165.79% |
| Q1 2022 | 2022-03-31 | 10.03 | — | — |
| Q4 2021 | 2021-12-31 | 8.77 | 7.91 | +920.77% |
| Q3 2021 | 2021-09-30 | 7.59 | — | — |
| Q2 2021 | 2021-06-30 | 3.45 | — | — |
| Q4 2020 | 2020-12-31 | 0.86 | — | — |
Indaptus Therapeutics current ratio trends
Over the last five fiscal years, Indaptus Therapeutics's current ratio increased from 0.86 to 1.51, a change of 0.65. The latest reported quarter, Q2 2026, shows 19.48.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indaptus Therapeutics source filings ↗